Signal · Supply Chain & Logistics
Anupam Rasayan eyes US, Europe pharma push after Bliss deal, one-third revenue from drugs
What the source reported
Source-reportedAnupam Rasayan India Ltd anticipates significant growth in its pharmaceutical segment over the next three years. The company expects pharmaceuticals to comprise one-third of overall revenue driven by the acquisition of Bliss GVS Pharma. Anupam's ability to offer integrated contract manufacturing services will facilitate its expansion in the US and Europe. Bliss currently operates at low capacity and presents opportunities for increased utilization.
- Publication
- The Economic Times - Industry · Trade Publication
- Published
- 7th October 2026
- Original report
- economictimes.indiatimes.com
ProcIntel stores what the source published in its feed — a headline, a summary and a link. It does not store or reproduce the full article.
What ProcIntel recorded
ProcIntel-derived- Category
- Supply Chain & Logistics
- Geography
- India
- Organisations
- None identified
- Collected
- 7th October 2026 · 06:46
Initial assessment ProcIntel's automatic, provisional read of this individual Signal -- Initial Significance and Initial Confidence, computed deterministically before any Event extraction or human review.
A provisional, automatically computed reading of this individual Signal, before Event extraction or human review. Not a final rating.
Initial Significance Moderate (36.0/100). Strongest contributor: Procurement Impact (27.0/30 points). Limiting factor: Impact-Scale Specificity (0.0/10 points). Initial Confidence Low (25.5/100, data sufficiency: Insufficient). Strongest contributor: Source Authority (20.0/40 points). Limiting factor: Specificity (0.0/20 points).
- Strongest contributor
- Procurement Impact
- Limiting factor
- Impact-Scale Specificity